WINTON GROUP Ltd Has $28.84 Million Position in Incyte Corporation $INCY

Posted by Brenda Bartman on Sep 10th, 2026

WINTON GROUP Ltd boosted its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 47.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 254,408 shares of the biopharmaceutical company’s stock after acquiring an additional 81,376 shares during the quarter. Incyte makes up approximately 0.9% of WINTON GROUP Ltd’s portfolio, making the stock its 12th largest holding. WINTON GROUP Ltd owned 0.13% of Incyte worth $28,840,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Fiduciary Financial Advisors bought a new position in shares of Incyte during the 2nd quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in Incyte during the fourth quarter worth $28,000. Smithfield Trust Co raised its holdings in Incyte by 135.0% during the fourth quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 162 shares in the last quarter. MUFG Securities EMEA plc acquired a new stake in shares of Incyte in the second quarter worth about $32,000. Finally, CYBER HORNET ETFs LLC acquired a new stake in shares of Incyte in the second quarter worth about $33,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Incyte

In related news, insider Pablo Cagnoni sold 10,801 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the transaction, the insider directly owned 183,200 shares in the company, valued at $23,002,592. The trade was a 5.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick Mayes sold 41,899 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $119.46, for a total value of $5,005,254.54. Following the completion of the transaction, the executive vice president directly owned 61,441 shares of the company’s stock, valued at approximately $7,339,741.86. This trade represents a 40.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on INCY shares. BMO Capital Markets reissued a “market perform” rating on shares of Incyte in a research note on Tuesday, September 1st. JPMorgan Chase & Co. raised their target price on shares of Incyte from $105.00 to $110.00 and gave the company a “neutral” rating in a research note on Thursday, July 23rd. Sanford C. Bernstein reiterated a “market perform” rating and issued a $104.00 target price on shares of Incyte in a report on Thursday, August 13th. Leerink Partners boosted their target price on shares of Incyte from $131.00 to $155.00 and gave the stock an “outperform” rating in a research report on Monday, August 3rd. Finally, Stifel Nicolaus set a $145.00 price target on shares of Incyte in a report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $124.05.

Check Out Our Latest Report on Incyte

Incyte Trading Up 1.3%

Shares of INCY stock opened at $126.01 on Thursday. Incyte Corporation has a 1 year low of $81.09 and a 1 year high of $132.60. The firm’s fifty day simple moving average is $121.58 and its 200 day simple moving average is $106.40. The firm has a market capitalization of $25.54 billion, a P/E ratio of 16.05, a price-to-earnings-growth ratio of 3.62 and a beta of 0.77.

Incyte (NASDAQ:INCY – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, beating analysts’ consensus estimates of $2.15 by $0.94. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the prior year, the firm earned $1.57 EPS. The business’s revenue was up 37.7% on a year-over-year basis. Equities research analysts anticipate that Incyte Corporation will post 2.64 EPS for the current fiscal year.

About Incyte

(Free Report)

Incyte Corporation is a biopharmaceutical company focused on discovering, developing and commercializing medicines for oncology and inflammatory diseases. Founded in 1991 and headquartered in Wilmington, Delaware, the company conducts research in areas including oncology, hematology, immunology and dermatology.

Incyte’s commercial portfolio includes Jakafi (ruxolitinib), a treatment for certain myelofibrosis, polycythemia vera and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib) for selected cancers involving abnormal FGFR signaling.